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Hypertension, dyslipidaemia, glucose intolerance (associated with insulin resistance and compensatory hyper-
insulinaemia) and other abnormalities are complementary coronary risk factors which often occur in association. A
familial trait for essential hypertension seems to coexist commonly with defects in carbohydrate and lipoprotein
metabolism which can be detected before the appearance of hypertension. Diabetes mellitus as well as obesity promotes the
development of hypertension and dyslipidaemia. Moreover, certain drugs used for antihypertensive therapy can further
modify lipoprotein and glucose metabolism.
Thiazides in high dosage and loop-diuretics can increase serum low-density-lipoprotein cholesterol (LDL-C) and/or
very-LDL-C and the total CI high-density lipoprotein cholesterol (HDL-C) ratio, while HDL-C is largely unchanged;
triglycerides (Tg) are also often elevated. Premenopausal women may be protected from this side effect. Whether diuretic-
induced dyslipidaemia is dose-dependent and low thiazide doses (i.e. hydrochlorothiazide ^ 12-5 mg daily) are less active,
awaits clarification. The diuretic-antihypertensive agent, indapamide, given at a dose of 2-5 mg. day~', seems to exert no
relevant effect on serum lipoprotein or glucose metabolism. The potassium-sparing diuretic, spironolactone, also may be
largely neutral with regard to lipids. Moreover, potassium sparing diuretics may possibly counteract, at least in part, a
dyslipidaemic influence of potassium-loosing diuretics in medium dose.
Drug-induced dyslipidaemia, as well as glucose intolerance, represent potentially adverse influences. In the hypertensive
population, effective blood pressure control with traditional drug therapy based on thiazide-type diuretics in high dosage led
to a distinct decrease in cerebrovascular morbidity and mortality, but a lesser decrease in coronary events. The prognostic
relevance of drug-induced metabolic changes such as dyslipidaemia, altered insulin sensitivity, and glucose intolerance
awaitsfurther clarification. It is of clinical interest that several of the generally available antihypertensive drugs seem to be
metabolically 'neutral' or sometimes perhaps even potentially beneficial with regard to the lipoprotein and glucose
metabolism.
Introduction disease161. A similar tendency is suspected for elevated
In the hypertensive population, high-dose diuretic therapy, b l o o d l e v e l s o f tnglyceride (Tg)-rich lipoproteins, particu-
with the older sympatholytics or the newer ^-blockers as l a r l v w h e n hypertriglyceridaemia is combined with a high
step two agents, and hydralazine-type vasodilators as step LDL-C/HDL-C ratio1781. In recent years it has become
three agents, have lowered blood pressure effectively. e v i d e n t t h a t s e v e r a l o f t h e dm& u s e d f o r s t a n d a r d a n t l "
Such therapy also improves overall cardiovascular and, in hypertensi w t h e r a p y may interact with the lipoprotein
particular, cerebrovascular prognosis, but has had less metabolism
benefit on the course of coronary heart disease and the
incidence of sudden death1'"41. In patients with mild hyper- _ _ . . .
, . . .̂ • . • . . J J Effects of diuretics
tension, a diuretic monotherapy in high dosage reduced
stroke but not the coronary complications, whereas Thiazide-type diuretics, administered as a monothera-
monotherapy with the y?-blocker propranolol slightly p g ^ c r egimen
1!MU;wo1, tend to increase serum total
improved both the cerebrovascular and coronary prog- cholesterol (C) (reported average + 4 % ) , serum LDL-C
nosis in non-smokers, but failed to provide such benefit to ( r e ported average +10%) (Fig. 1) as well as very low
smokers'51. Suspicion has been growing that conventional density lipoprotein cholesterol (VLDL-C). HDL-C (Fig.
antihypertensive therapy may unfavourably influence j) a n d i t s m a j o r apoproteins A, and A2 are on average
coronary risk factor(s) other than high blood pressure, unchanged. Thus, the LDL/HDL-C and total C/HDL-C
Interactions with cardiac hypertrophy, electrolytes, carbo- r a t ; o s a r e frequently elevated. Loop diuretics, such as
-
hydrate and lipoprotein metabolism, angiotensin II, frusemide, mefruside, piretanide and muzolimine also
catecholamines, endothelial function and clotting factors t e n d t o j n c r e a s e these ratios*
9-"1. Moreover, slight
are under particular consideration. increases in VLDL-triglycerides (VLDL-Tg) and/or total
A decrease in high-density lipoprotein cholesterol Tg (on ave rage+9%) were noted in most, although not
(HDL-C) or increase in low density lipoprotein choles- a n s t udies with thiazide-type or loop-diuretics,
terol (LDL-C) both augment the risk for coronary heart A c n t i c a i aspect o f a n y metabolic side effect is its course
This work was supported by the Swiss National Science Foundation. Over time. Diuretic-induced dyslipidaemia persists for at
Correspondent: Prof P. Weidmann, Medizinisct* UniversitaU-Poliklmik, I e a S t ' V e a r ' w i t h S O m e S t u d i e S documenting this alteration
Freiburgstrasse 3, CH-3010 Bern, Switzerland. up to 6 years (Fig. 1). In the Multiple Risk Factor
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Figure 1 Percentage changes in serum total cholesterol, LDL-C and HDL-C in relation to the duration
of a therapy with thiazide-type (hatched bars) or certain loop diuretics (closed bars); n ;> 10 subjects per
study. Asterisks denote differences between study groups on diuretics as compared with study groups on
no diuretics or no antihypertensive drugs, see1231 and1"5. (Reproduced with permission1"1).
Intervention Trial (MRFIT)1231 and the Hypertension
Detection and Follow-up Program (HDFPf261, a
reduction in total cholesterol occurring in groups
receiving no diuretics or any antihypertensive treatment,
respectively, was blunted in groups receiving thiazide-
type diuretics, even after 5 to 6 years of such monotherapy
(Figs 2 and 3). In a further long-term study, cessation of
hydrochlorothiazide (average dose 51 mg. day"1) after a
mean treatment duration of 5-2 years in 23 hypertensive
patients resulted in a 7% decrease in total cholesterol and
a 12% reduction in LDL-C'3" (Fig. 4).
Gender and the menopausal state may play a role in the
interaction between diuretics and lipoproteins. In post-
menopausal women, chlorthalidone administered in high
dosage produced changes in serum total cholesterol and
LDL-C similar to those in men; no changes were seen in
premenopausal women'32' (Fig. 5). This points to a
'protective' influence of the premenopausal state. It seems
that oestrogens increase the number of hepatic LDL-
binding sites and stimulate the hepatic uptake of
chylomicron-remnants'33'.
The development of dyslipidaemia may also be linked
to the type and dose of the administered diuretics. The
potassium-sparing diuretic, spironolactone, may be largely
neutral with regard to plasma lipid levels'34"421 (Fig. 6),
although reported data on LDL-C are scarse and those
on HDL-C also too limited to allow a firm conclusion.
Effects of a monotherapy with triamterene or amiloride
on the plasma lipid profile are largely unknown, one
report describing a mild decrease in total C (— 10%) after
7 weeks of amiloride treatment in 13 hypertensive men'43'.
Combinations of a potassium-loosing diuretic (almost
always a thiazide in medium dosage, for instance hydro-
chlorothiazide 25-50 mg . day"1) with a potassium-
sparing diuretic may be less prone to alter the lipoprotein
metabolism than high-dose thiazides or loop-diuretics. A
comprehensive analysis of reported studies reveals only
minimal changes in serum total cholesterol and minor
changes in total Tg on such combinations including
either spironolactone (25-50mg.day"'), triamterene
(approximately 20-100mg.day"1) or amiloride (2-
lOmg.day"')1"'44-581 (Fig. 7). As far as we know
from reports, HDL-C tended to parallel total choles-
teroj[ii.48.5o.5iJ5.58J Nevertheless, interpretation is some-
what limited due to incomplete information on gender
and/or the menopausal state in some reports.
The diuretic-antihypertensive agent, indapamide, in
the usual antihypertensive dose of 2-5mg.day"1, does
not produce dyslipidaemia'10"59'. (The methyl-substituted
isoindoline part of indapamide differentiates this agent
structurally from chlorthalidone, hydrochlorothiazide,
furosemide and ticrynafen.) Compared with the rather
low effective antihypertensive dose of indapamide,
unnecessarily high daily doses of chlorthalidone, hydro-
chlorothiazide (50 to lOOmg.day"1) or other thiazides
were generally utilized in studies focussing on interactions
with lipoproteins as well as in the large therapeutic
programmes in hypertensive patients.
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Figure 4 Percentage changes in serum cholesterol fractions 4-6
weeks after cessation of long-term antihypertensive treatment (mean
duration 5-2 years) with the diuretic hydrochlorothiazide (average
dose 51 mg . day"1; n = 23) or the /9-blocker atenolol (average dose
75 mg. day"1; n = 17). Changes in total triglycerides were + 4 % or
— 14% after discontinuation of hydrochlorothiazide or atenolol,
respectively. (Data based on1311).
24- months 72 months
Figure 2 Absolute changes from baseline in serum total cholesterol,
sum of LDL-C and VLDL-C and HDL-C (top) and in total triglycer-
ides (bottom) in men in the M RFIT after 24 and 72 months of follow-
up. All patients were on diet. Open bars represent patients without
diuretics; closed bars, patients with diuretic therapy. (Data based
on"23").
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Figure 3 Percentage changes from baseline in serum total choles-
terol of stepped care cohorts of patients on chlorthalidonc therapy,
combination therapy or no therapy, during a follow-up of 5 years in
the Hypertension Detection and Follow-up Program. (Data based
0 1 - Apoprotein B
Figure 5 Effect of treatment with chlorthalidone in high dosage
(100 mg. day ' x 6 weeks) on serum total cholesterol, LDL-choles-
terol and apoprotein B in pro- or postmenopausal women. Mean
values ± SEM are shown. The P values denote statistically significant
differences between placebo (23) and chlorthalidone treatment ( • ) ;
* = /><0-001; **/> = 0-05. (Data based onP2!).
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Figure 6 Percentage changes in serum total cholesterol and tri-
glycerides in relation to the duration of a monotherapy with
spironolactone. n ^ 13 subjects per study.
Average changes in all reported subjects are given as mean ± SD.
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Figure 7 Average percentage changes in serum total cholesterol,
tnglycendes and potassium in reported studies using combinations
of a potassium-loosing diuretic (almost always thiazides) with a
potassium-sparing diuretic.
Mean±SD. There were no significant differences between combi-
nations including either spironolactone, triamterene or amiloride.
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Figure 8 Percentage changes in serum total and LDL cholesterol
after I year of therapy with different types of agents in the Treatment
of Mild Hypertension Study. (Data based on1"1).
Since effects of thiazides on serum potassium, glucose
and uric acid are dose-dependent, in low doses they may
be also less prone to modify the lipoprotein profile'601.
Nevertheless, similar increases in serum total cholesterol
and LDL-C were noted in hypertensive men receiving
during up to 42 months either <50 or >50mg hydro-
chlorothiazide daily'271, in nine subjects treated during ;> 6
months with hydrochlorothiazide, 50mg.day~', and
then during 6 months 25 mg. day"1'61', or in nine post-
menopausal women receiving during subsequent 1 month
periods 12-5 as compared with 112-5mg hydrochloro-
thiazide daily*621. On the other hand, measurements in
patients with mild hypertension (average age 55 years,
38% women) after 1 year of therapy with nutritional-
hygienic intervention combined with different types of
antihypertensive drugs revealed that low dose chlorthali-
done (15mg.day ' ) was associated with minimal
increases in total cholesterol ( + 0-5%) and LDL-C
(+1%), whereas administration of placebo or drugs
thought to be neutral with regard to total and LDL-C
(amlodipine, enalapril) were accompanied by mild
decreases in total cholesterol ( - 2 to - 3 % ) and LDL-C
( - 1 to - 3 % ) (Fig. 8). Nevertheless, changes in HDL-C/
total cholesterol ratio did not differ significantly between
low-dose chlorthalidone (+ 5%) and the other treatments
( + 8 to+10%) (Fig. 9)1631.
Possible mechanisms
The mechanisms of diuretic-induced dyslipidaemia are
still unclear. Nevertheless, diuretics, particularly when
administered in high dosage, can slightly increase sym-
pathetic nervous activity1641 and/or levels of circulating
norepinephrine. This may, in turn, promote lipolysis'651,
stimulate the hepatic synthesis of cholesterol sub-
sequently secreted as VLDL and probably also raise the
>•
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Figure 9 Percentage changes in serum HDL cholesterol or the
HDL/total cholesterol ratio after 1 year of therapy with different
types of agents in the treatment of mild hypertension study. (Data
based on1"1).
atherogenic serum cholesterol fraction. Dependence of
the latter on noradrenergic modulation is suggested by
a positive correlation between plasma norepinephrine
and LDL + VLDL-C both before and after sympathetic
neurone blockade in patients with essential hypertension
or renal failure1661. Thiazide-type and loop diuretics can
also impair insulin sensitivity*671. Changes in potassium
may possibly play a role in this interaction1"1. The latter
and/or the resulting compensatory hyperinsulinaemia are
known to promote hypertriglyceridaemia, a tendency for
low HDL-C, and atherogenesis1681. It can be hypothesized
that, with intact lipoprotein lipase activity, excess VLDL
could be metabolized to LDL-C, thereby contributing
perhaps also to increased total serum cholesterol
concentration.
Other antihypertensive agents
Several /?-blockers tend to increase Tg and decrease
HDL-C. These changes are most prominent on unselec-
tive /?,+2-blockers without intrinsic sympathomimetic
activity (ISA), less pronounced on selective /?,-blockers
without ISA, discrete on /?-blockers with modest ISA and
largely absent on /J-blockers with pronounced ISA19'12'.
Some /J-blockers can also slightly reduce insulin sensitivity
and/or secretion and during long-term treatment impair
glucose tolerance, particularly when they are adminis-
tered in combination with diuretics1301. Celiprolol, a /?,-
blocker with concomitant /?2-agonism and ou-antagonism,
tends to decrease Tg and increase HDL-C130^.
Considering combination treatment, diuretic-induced
increases in LDL-C may, at least in the short-term, be
prevented by the concomitant administration of certain
/J-blockers'69-701.
Postsynaptic a,-blockers can slightly decrease Tg,
LDL-C and the total C/HDL-C ratio, while insulin
sensitivity, insulin secretion and glucose tolerance may
tend to be improved'12301. Some other sympatholytics are
largely neutral with regard to lipoproteins and glucose
tolerance.
ACE inhibitors, calcium channel blockers and the
serotonin2-receptor blocker ketanserin do not adversely
affect serum lipoproteins112-30"1. ACE inhibitors tend to
decrease serum total Tg and slightly improve insulin sensi-
tivity and glucose tolerance1301. The latter has been largely
unchanged in clinical studies of calcium channel blockers
or ketanserin; nevertheless, whether or not clinical
treatment with such agents can produce subtle changes in
insulin sensitivity or secretion is presently unclear.
Relevance and outlook
Whether the lipoprotein changes induced by certain
antihypertensive drugs can per se modify the long-term
prognosis of patients so treated is still unclear. In patients
with high serum cholesterol concentration (pre-treatment
C>6-5 mM. 1~'), long-term C-lowering with either diet or
drugs produced a 1-5% decrease in coronary heart disease
for every 1 % reduction in serum cholesterol. Whether this
correlation also holds for both decreases and increases
from initially normal or mildly elevated serum cholesterol
levels is not yet known. Therefore, attempts to calculate a
potential impact of diuretic-induced increases in serum
total cholesterol and LDL-C on coronary prognosis
would be speculative.
Whatever the relative contribution of dyslipidaemia,
diuretic therapy may concomitantly aggravate several
potential cardiac risk factors, including impaired
insulin sensitivity with compensatory hyperinsulinaemia,
electrolyte imbalance, sympathetic and angiotensin II-
stimulation, and others. Although it has been difficult to
demonstrate a primary preventive effect of /?-blockers on
coronary prognosis, such agents, and particularly those
without ISA, have been found to be effective at least in the
secondary prevention of myocardial infarction. There-
fore, /?-blockers may possibly have a beneficial effect on
some key steps involved in atheroma formation172-731. It
follows that diuretics and ^-blockers have done at least
'some good', while a prognostic efficacy of newer drug
classes, such as calcium channel blockers, ACE-inhibitors,
postsynaptic a-\ blockers and S2-blockers remains to be
demonstrated.
Finally, it is important to note that observations on
interactions of antihypertensive agents with lipoproteins
have so far been limited largely to scrum concentrations.
However, lipid binding to vascular cells, the uptake, con-
centrations and metabolic processes in vascular cells rather
than in the blood stream are decisive for atherogenesis,
and effects of the different antihypertensive agents at the
cellular level remain to be investigated. Therefore, possible
differential indications for the various antihypertensive
drugs are only beginning to emerge. Still, at this stage, it is
of clinical interest that several of the generally available
antihypertensive drugs seem to be metabolically 'neutral'
or sometimes perhaps even potentially beneficial with
regard to the lipoprotein and glucose metabolism.
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